| The blockade of immune checkpoints in cancer immunotherapy | Nature Reviews Cancer | 2012 | 8.1K |
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | New England Journal of Medicine | 2015 | 5.6K |
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 5.5K |
| The fundamental role of epigenetic events in cancer | Nature Reviews Genetics | 2002 | 4.3K |
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | New England Journal of Medicine | 2015 | 3.7K |
| The epigenomics of cancer | Cell | 2007 | 3.5K |
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade | Science | 2017 | 3.3K |
| Cancer genes and the pathways they control | Nature Medicine | 2004 | 3.2K |
| Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 | Cell | 2004 | 3.1K |
| The consensus coding sequences of human breast and colorectal cancers | Science | 2006 | 2.8K |
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Science Translational Medicine | 2014 | 2.7K |
| Gene silencing in cancer in association with promoter hypermethylation | New England Journal of Medicine | 2003 | 2.7K |
| High frequency of mutations of the PIK3CA gene in human cancers | Science | 2004 | 2.7K |
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | New England Journal of Medicine | 2015 | 2.5K |
| c-Myc-regulated microRNAs modulate E2F1 expression | Nature | 2005 | 2.4K |
| Immune checkpoint blockade: a common denominator approach to cancer therapy | Cancer Cell | 2015 | 2.4K |
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Journal of Clinical Oncology | 2010 | 2.2K |
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Journal of Clinical Oncology | 2014 | 1.7K |
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Clinical Cancer Research | 2014 | 1.7K |
| A draft map of the human proteome | Nature | 2014 | 1.5K |
| Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Nature Reviews Cancer | 2016 | 1.4K |
| Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment | Nature Reviews Immunology | 2007 | 1.4K |
| Estrogen carcinogenesis in breast cancer | New England Journal of Medicine | 2006 | 1.3K |
| Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | 2016 | 1.3K |
| Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues | Advanced Drug Delivery Reviews | 2009 | 1.2K |
